# The role of L3 skeletal muscle index in the diagnosis and prognosis prediction of sarcopenia and malnutrition in cancer patients

## TL;DR

This study explores how the L3 skeletal muscle index helps diagnose sarcopenia and predict survival in cancer patients.

## Contribution

The study introduces L3-SMI as a potential marker for malnutrition and survival prediction in cancer patients.

## Key findings

- 99 patients (34.86%) were diagnosed with malnutrition using L3-SMI and GLIM criteria.
- Malnourished patients had a significantly higher risk of mortality (HR = 1.954).
- Kaplan-Meier analysis showed poorer overall survival for malnourished patients.

## Abstract

This study investigated the validity of the third lumbar skeletal muscle index (L3-SMI) as a marker of reduced muscle mass (RMM) in hospitalized cancer patients. It further evaluated the diagnostic accuracy of L3-SMI for malnutrition according to the Global Leadership Initiative on Malnutrition (GLIM) criteria and examined the relationship between L3-SMI and long-term survival in cancer patients.

A retrospective analysis was conducted between April 2014 and November 2018 at Daping Hospital, affiliated with Army Medical University. A total of 284 cancer patients were included. Analytical methods used in this study comprised receiver operating characteristic (ROC) curve analysis, Kaplan-Meier survival analysis, Cox proportional hazards regression models, time-dependent ROC curves, and kappa statistics.

Using the GLIM criteria with L3-SMI, 99 patients (34.86%) were diagnosed with malnutrition. Cox regression analysis revealed that patients diagnosed with malnutrition based on L3-SMI had the highest hazard ratio (HR = 1.954, 95% CI = 1.291-2.958) for mortality. Kaplan-Meier survival analysis showed that malnourished patients had significantly poorer overall survival. The agreement between GLIM-SMI and the Patient-Generated Subjective Global Assessment (PG-SGA) in diagnosing malnutrition was moderate (Kappa = 0.550). Time-dependent ROC curve analysis demonstrated that the area under the curve (AUC) for GLIM-SMI was 0.617, 0.578, and 0.578 at 1-year, 3-year, and 5-year survival monitoring, respectively.

The L3-SMI may be a useful alternative indicator for reduced muscle mass in hospitalized cancer patients. GLIM evaluated by incorporation of L3-SMI is independently associated with long-term survival outcomes in this patient population. The prognostic significance of GLIM-L3-SMI requires further validation in other cohorts with large sample size.